Joanne M Bowen1, Rachel J Gibson2, Janet K Coller3, Nicole Blijlevens4, Paolo Bossi5, Noor Al-Dasooqi3, Emma H Bateman3, Karen Chiang6, Charlotte de Mooij4, Bronwen Mayo2, Andrea M Stringer2, Wim Tissing7, Hannah R Wardill3, Ysabella Z A van Sebille2, Vinisha Ranna8, Anusha Vaddi9, Dorothy Mk Keefe3, Rajesh V Lalla10, Karis Kin Fong Cheng11, Sharon Elad9. 1. Adelaide Medical School, University of Adelaide, Adelaide, Australia. joanne.bowen@adelaide.edu.au. 2. Division of Health Sciences, University of South Australia, Adelaide, Australia. 3. Adelaide Medical School, University of Adelaide, Adelaide, Australia. 4. Radboud University Medical Centre, Nijmegen, The Netherlands. 5. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health - Medical Oncology, University of Brescia, Brescia, Italy. 6. St Vincent's Hospital, Melbourne, Australia. 7. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 8. Department of Oral and Maxillofacial Surgery, The Mount Sinai Hospital, New York, NY, USA. 9. Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA. 10. Section of Oral Medicine, University of Connecticut Health, Farmington, CT, USA. 11. Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Abstract
PURPOSE: The aim of this study was to update the clinical practice guidelines for the use of agents for the prevention and/or treatment of gastrointestinal mucositis (GIM). METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, and No Guideline Possible. RESULTS: A total of 78 papers across 13 interventions were examined of which 25 were included in the final review. No new guidelines were possible for any agent due to inadequate and/or conflicting evidence. Existing guidelines for probiotics and hyperbaric oxygen were unchanged. CONCLUSIONS: Of the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM.
PURPOSE: The aim of this study was to update the clinical practice guidelines for the use of agents for the prevention and/or treatment of gastrointestinal mucositis (GIM). METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, and No Guideline Possible. RESULTS: A total of 78 papers across 13 interventions were examined of which 25 were included in the final review. No new guidelines were possible for any agent due to inadequate and/or conflicting evidence. Existing guidelines for probiotics and hyperbaric oxygen were unchanged. CONCLUSIONS: Of the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM.
Authors: Rachel J Gibson; Dorothy M K Keefe; Rajesh V Lalla; Emma Bateman; Nicole Blijlevens; Margot Fijlstra; Emily E King; Andrea M Stringer; Walter J F M van der Velden; Roger Yazbeck; Sharon Elad; Joanne M Bowen Journal: Support Care Cancer Date: 2012-11-10 Impact factor: 3.603
Authors: Dorothy M Keefe; Mark M Schubert; Linda S Elting; Stephen T Sonis; Joel B Epstein; Judith E Raber-Durlacher; Cesar A Migliorati; Deborah B McGuire; Ronald D Hutchins; Douglas E Peterson Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Stephen T Sonis; Linda S Elting; Dorothy Keefe; Douglas E Peterson; Mark Schubert; Martin Hauer-Jensen; B Nebiyou Bekele; Judith Raber-Durlacher; J Peter Donnelly; Edward B Rubenstein Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Alan Carlotto; Virginia L Hogsett; Elyse M Maiorini; Janet G Razulis; Stephen T Sonis Journal: Pharmacoeconomics Date: 2013-09 Impact factor: 4.981
Authors: Andrea M Stringer; Noor Al-Dasooqi; Joanne M Bowen; Thean H Tan; Maryam Radzuan; Richard M Logan; Bronwen Mayo; Dorothy M K Keefe; Rachel J Gibson Journal: Support Care Cancer Date: 2013-02-10 Impact factor: 3.603
Authors: Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad Journal: Cancer Date: 2014-02-25 Impact factor: 6.860
Authors: Wanessa Miranda-Silva; Wagner Gomes-Silva; Yehuda Zadik; Noam Yarom; Abdul Rahman Al-Azri; Catherine H L Hong; Anura Ariyawardana; Deborah P Saunders; M Elvira Correa; Praveen R Arany; Joanne Bowen; Karis Kin Fong Cheng; Wim J E Tissing; Paolo Bossi; Sharon Elad Journal: Support Care Cancer Date: 2020-11-06 Impact factor: 3.603
Authors: Wael Saber; Patricia Steinert; Mei-Jie Zhang; Min Chen; Andrea Pope; Armand Keating; John R Wingard; Karen Ballen; Patrick Stiff; Miguel-Angel Perales; Stephen Forman; Richard Champlin; Amelia Langston; Mattias Rudebeck; Mary Horowitz Journal: Transplant Cell Ther Date: 2021-07-02
Authors: H R Wardill; A R da Silva Ferreira; S Lichtenberg Cloo; R Havinga; H J M Harmsen; W P Vermeij; W J E Tissing Journal: Gut Microbes Date: 2020-11-09